Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alpine Immune Sciences

Alpine Immune Sciences
2015 FOUNDED
PUBLIC STATUS
41-50 EMPLOYEES
ALPN STOCK SYMBOL
1 INVESTMENTS
$2.66 SHARE PRICE (As of Monday Closing)
Description

Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins.

Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 201 Elliot Avenue West
  • Suite 230
  • Seattle, WA 98119
  • United States

+1 (206) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Alpine Immune Sciences’s full profile, request a free trial.

Alpine Immune Sciences Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.25 - $8.24 $49.4M $2.60 -$3.02 22.8K 18.6M

Alpine Immune Sciences Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 18,637 (6,340) 73,263 (31,370)
Revenue 567 705 1,731 2,950
EBITDA (47,777) (37,442) (8,132) (1,119)
Net Income (47,511) (36,487) (7,783) (1,232)
Total Assets 70,087 54,873 85,222 12,595
Total Debt 14,641 4,203 5,034 113
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alpine Immune Sciences Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Alpine Immune Sciences‘s full profile, request access.

Request full access to PitchBook

Alpine Immune Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Alpine Immune Sciences‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Alpine Immune Sciences Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 25-Jul-2017 000000000000000000 0000 Biotechnology 00000000 0000 00
To view this company’s complete investment and acquisition history, request access »

Alpine Immune Sciences Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Alpine Immune Sciences‘s full profile, request access.

Request full access to PitchBook

Alpine Immune Sciences Executive Team (7)

Name Title Board
Seat
Contact
Info
Mitchell Gold MD Chief Executive Officer & Chairman
Paul Rickey Chief Financial Officer & Chief Accounting Officer
David Miller Director & Secretary
Stanford Peng Ph.D Executive Vice President & Executive
Michael Kornacker Ph.D Co-Founder, Senior Vice President Protein Engineering and Board Member

1 Former Executive

You’re viewing 5 of 7 executives. Get the full list »

Alpine Immune Sciences Board Members (7)

Name Representing Role Since Contact
Info
Christopher Peetz Self Board Member 000 0000
James Topper Ph.D Self Board Member 000 0000
Jay Venkatesan MD Self Board Member 000 0000
Mitchell Gold MD Alpine Immune Sciences Chief Executive Officer & Chairman 000 0000
Peter Thompson MD OrbiMed Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 7 board members. Get the full list »